157 related articles for article (PubMed ID: 36871894)
1. Modified NAP test: A simple and Responsive Nitrosating Methodology for Risk Evaluation of NDSRIs.
Sharma N; Patel R; Bothara T; Jain S; Shah RP
J Pharm Sci; 2023 May; 112(5):1333-1340. PubMed ID: 36871894
[TBL] [Abstract][Full Text] [Related]
2. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals.
Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Rojsitthisak P
Saudi Pharm J; 2023 Feb; 31(2):295-311. PubMed ID: 36942272
[TBL] [Abstract][Full Text] [Related]
3. Current status and prospects of development of analytical methods for determining nitrosamine and N-nitroso impurities in pharmaceuticals.
Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Thitikornpong W; Rojsitthisak P
Talanta; 2023 Mar; 254():124102. PubMed ID: 36470020
[TBL] [Abstract][Full Text] [Related]
4. A Nitrite Excipient Database: A Useful Tool to Support N-Nitrosamine Risk Assessments for Drug Products.
Boetzel R; Schlingemann J; Hickert S; Korn C; Kocks G; Luck B; Blom G; Harrison M; François M; Allain L; Wu Y; Bousraf Y
J Pharm Sci; 2023 Jun; 112(6):1615-1624. PubMed ID: 35500671
[TBL] [Abstract][Full Text] [Related]
5. N-Nitrosamine Formation in Pharmaceutical Solid Drug Products: Experimental Observations.
Moser J; Ashworth IW; Harris L; Hillier MC; Nanda KK; Scrivens G
J Pharm Sci; 2023 May; 112(5):1255-1267. PubMed ID: 36736774
[TBL] [Abstract][Full Text] [Related]
6. The Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals.
Schlingemann J; Burns MJ; Ponting DJ; Martins Avila C; Romero NE; Jaywant MA; Smith GF; Ashworth IW; Simon S; Saal C; Wilk A
J Pharm Sci; 2023 May; 112(5):1287-1304. PubMed ID: 36402198
[TBL] [Abstract][Full Text] [Related]
7. Revisiting the Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals.
Burns MJ; Ponting DJ; Foster RS; Thornton BP; Romero NE; Smith GF; Ashworth IW; Teasdale A; Simon S; Schlingemann J
J Pharm Sci; 2023 Dec; 112(12):3005-3011. PubMed ID: 37805074
[TBL] [Abstract][Full Text] [Related]
8. Genotoxicity evaluation of a valsartan-related complex N-nitroso-impurity.
Glowienke S; Onken U; Elhajouji A; Muthusamy S; Sangana R; Martus HJ; Bedman T; Hartmann A
Regul Toxicol Pharmacol; 2022 Oct; 134():105245. PubMed ID: 35988810
[TBL] [Abstract][Full Text] [Related]
9. Trace Aldehydes in Solid Oral Dosage Forms as Catalysts for Nitrosating Secondary Amines.
Harmon P
J Pharm Sci; 2023 May; 112(5):1216-1219. PubMed ID: 36336102
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the Formaldehyde-Catalyzed NNitrosation of Dialkyl Amines: An Automated Experimental and Kinetic Modelling Study Using Dibutylamine.
Diab S; Ferrini P; Dominey AP; Whiting MP; Wickens JR; Ashworth IW; Rainey TJ
J Pharm Sci; 2024 Jun; 113(6):1624-1635. PubMed ID: 38307493
[TBL] [Abstract][Full Text] [Related]
11. Nitrosation of drugs under in-vivo conditions.
Walters CL; Gillatt PN; Palmer RC; Smith PL; Reed PI
IARC Sci Publ; 1987; (84):351-4. PubMed ID: 3679400
[TBL] [Abstract][Full Text] [Related]
12. Flow Electrochemistry for the N-Nitrosation of Secondary Amines.
Ali R; Babaahmadi R; Didsbury M; Stephens R; Melen RL; Wirth T
Chemistry; 2023 Jun; 29(32):e202300957. PubMed ID: 36975121
[TBL] [Abstract][Full Text] [Related]
13. Formation of N-nitrosamines by micelle-catalysed nitrosation of aliphatic secondary amines.
Breider F; Salihu I; von Gunten U
Environ Sci Process Impacts; 2018 Oct; 20(10):1479-1487. PubMed ID: 30252010
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of nitrosamine formation by ascorbic acid.
Tannenbaum SR; Wishnok JS; Leaf CD
Am J Clin Nutr; 1991 Jan; 53(1 Suppl):247S-250S. PubMed ID: 1985394
[TBL] [Abstract][Full Text] [Related]
15. Role of Carbonyl Compounds for
Pan Y; Breider F; Barrios B; Minakata D; Deng H; von Gunten U
Environ Sci Technol; 2024 Mar; 58(10):4792-4801. PubMed ID: 38427382
[No Abstract] [Full Text] [Related]
16. Risk assessment for nitrosated pharmaceuticals: A future perspective in drug development.
Schmidtsdorff S; Neumann J; Schmidt AH; Parr MK
Arch Pharm (Weinheim); 2022 Apr; 355(4):e2100435. PubMed ID: 35088435
[TBL] [Abstract][Full Text] [Related]
17. Nitrosated Active Pharmaceutical Ingredients - Lessons Learned?
Holzgrabe U
J Pharm Sci; 2023 May; 112(5):1210-1215. PubMed ID: 36720391
[TBL] [Abstract][Full Text] [Related]
18. Bumetanide as a Model NDSRI Substrate: N-nitrosobumetanide Impurity Formation and its Inhibition in Bumetanide Tablets.
Shakleya D; Asmelash B; Alayoubi A; Abrigo N; Mohammad A; Wang J; Zhang J; Yang J; Marzan TA; Li D; Shaklah M; Alsharif FM; Desai S; Faustino PJ; Ashraf M; O'Connor T; Vera M; Raw A; Sayeed VA; Keire D
J Pharm Sci; 2023 Dec; 112(12):3075-3087. PubMed ID: 37364772
[TBL] [Abstract][Full Text] [Related]
19. Quantum Mechanical Assessment of Nitrosamine Potency.
De S; Thapa B; Sayyed FB; Frank SA; Cornwell PD; Jolly RA
Chem Res Toxicol; 2024 Jun; 37(6):1011-1022. PubMed ID: 38804898
[TBL] [Abstract][Full Text] [Related]
20. Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches.
Bhirud D; Agrawal G; Shah H; Patel A; Palkar MB; Bhattacharya S; Prajapati BG
Curr Top Med Chem; 2024; 24(6):503-522. PubMed ID: 38321910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
